Pao Yu Chuang Net Worth

What's Pao Chuang's mailing address?

Pao's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE J - 608, HOUSTON, TX, 77021.

Insiders trading at Salarius Pharmaceuticals

Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum y Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.

What does Salarius Pharmaceuticals do?

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Salarius Pharmaceuticals executives and stock owners

Salarius Pharmaceuticals executives and other stock owners filed with the SEC include:

• William McVicar,
  Chairman of the Board
• David J. Arthur M.B.A.,
  CEO, Pres & Director
• David Arthur,
  President, Chief Executive Officer, Director
• Mark Rosenblum,
  Chief Financial Officer, Executive Vice President - Finance
• Mark J. Rosenblum,
  Exec. VP of Fin. & CFO
• Maureen McEnroe,
  IR Contact Officer
• Jonathan Lieber,
  Independent Director
• Arnold Hanish,
  Independent Director
• Tess Burleson,
  Independent Director
• Paul Lammers,
  Lead Independent Director
• Bruce McCreedy,
  Interim Chief Scientific Officer and Director
• Nadeem Mirza,
  Senior Vice President - Clinical Development
• Dr. Daniela Y. Santiesteban,
  Director of Research and Bus. Devel.
• Dr. Nadeem Q. Mirza M.D., M.P.H.,
  Sr. VP of Clinical Devel.
• Jonathan P Northrup,
  Director
• Pao Yu Chuang,
  Controller
• Scott Jordan,
  Chief Financial Officer